Urinary Bladder Overactive
3
Pipeline Programs
1
Companies
2
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
Competitive Landscape
1 companies ranked by most advanced pipeline stage
AstellasChina - Shenyang
2 programs1
1
Solifenacin succinatePhase 31 trial
mirabegronN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstellasSolifenacin succinate
Astellasmirabegron
Clinical Trials (2)
Total enrollment: 3,353 patients across 2 trials
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
Start: Mar 2014Est. completion: Sep 20161,829 patients
Phase 3Completed
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
Start: Jan 2015Est. completion: Aug 20171,524 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space